— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected.
— Revenues grew 62% to $94.6 million, vs. $88.4 million expected.
— Research and development expenses were $62.6 million, compared to $53.1 million last year.
— FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from the previous range of $320 million to $330 million.
— ACAD shares fell 0.81% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Infographic: Key highlights from Disney’s (DIS) Q2 2024 earnings results
The Walt Disney Company (NYSE: DIS) reported second quarter 2024 earnings results today. Revenues increased 1% year-over-year to $22.1 billion. Net loss attributable to The Walt Disney Company was $20
Earnings Preview: Alibaba likely to report mixed results for Q4
Alibaba Group Holding Limited (NYSE: BABA) will be reporting fourth-quarter 2024 financial results next week. Over the years, the e-commerce giant successfully diversified its business and emerged as a major
A look at Tyson Foods’ (TSN) expectations for the remainder of FY2024
Shares of Tyson Foods, Inc. (NYSE: TSN) fell over 7% on Monday. The stock has gained 7% year-to-date. The company delivered mixed results for the second quarter of 2024, with
